Microdosing GLP-1 for menopause has almost no direct research yet: no trial has tested sub-label doses in menopausal women. What exists are standard-dose weight studies. If weight is your goal, microdosed tirzepatide from telos rx is prescribed for weight management only.
That is the honest starting point. Below, you will see what the studies measured, where the gaps are, and how HRT fits in. You will also see what to ask before you start.
What microdosing GLP-1 for menopause actually means
Microdosing is not an FDA-recognised dosing category. It is a popular term for a provider-prescribed dose below the standard labelled titration schedule. That makes it off-label.
Published evidence for sub-label doses is limited. The studies you see quoted online mostly used standard doses. Compounded tirzepatide is not FDA-approved, and it is not the same product as Zepbound or Mounjaro.
For a deeper primer on the term, read what counts as a microdose of tirzepatide.
Microdosing GLP-1 menopause weight gain: what is changing in your body
Many women notice weight gain around the middle during the menopause transition. Researchers link this to falling estrogen, shifts in where fat is stored, and gradual loss of lean mass.
Sleep disruption, stress and less activity can add to it. None of this means you did anything wrong. It does mean the same habits can produce different results than they did at 35.
This is why GLP-1 medications draw interest at midlife. They act on appetite and fullness signals. But interest is not evidence, and the menopause-specific evidence is thin.
What the research shows: three findings
Here is what published sources actually report. Each one is framed as evidence, not a promise of any result.
| Source | Design | Dose studied | Microdose data? |
|---|---|---|---|
| Nicolau et al., 2025 | Small observational study, 4 months | Semaglutide 1 mg weekly | No |
| Hurtado et al., 2024 | Retrospective cohort, 106 women | Standard semaglutide | No |
| Zepbound FDA label | Prescribing information | Labelled titration schedule | No |
Finding 1: lower than maximum semaglutide in menopausal women
A 2025 study by Nicolau and colleagues compared postmenopausal and premenopausal women on semaglutide 1 mg for four months (PubMed). The authors called this a low dose because it sits below the top weight management dose.
They reported that weight change and fat mass change were similar between the two groups. Note the limits. It was small, observational and short. And 1 mg is a standard labelled semaglutide dose, not a microdose.
Finding 2: hormone therapy users in a semaglutide cohort
A 2024 Mayo Clinic study reviewed records of postmenopausal women using semaglutide for overweight or obesity (PubMed). Women also using menopause hormone therapy had a greater average weight response than women who were not.
This was retrospective, with only 16 women in the hormone therapy group. It shows an association, not cause and effect. The authors themselves called for larger studies. It did not test microdoses.
Finding 3: what the tirzepatide label says about dosing
The Zepbound label sets a starting dose of 2.5 mg once weekly for 4 weeks, increasing in 2.5 mg steps (DailyMed). The label describes 2.5 mg as a starting dose only, not a maintenance dose.
Any dose below that schedule is off-label. The label contains no data on long-term sub-label use, in menopause or anywhere else.
Where there is no microdose data
Be clear-eyed about the gaps. As of publication, we found no published trial of microdosed GLP-1 or tirzepatide in menopausal women.
- No microdose data on hot flashes or night sweats.
- No microdose data on sleep, mood or brain fog.
- No microdose data on bone density or muscle in menopause.
- No long-term safety data for sub-label doses in this group.
Social media posts and clinic blogs may say otherwise. Read claims about menopause symptoms with caution. GLP-1 medications are not FDA-approved for menopause.
Weight management, at a dose set for you
telos rx offers compounded microdosed tirzepatide for weight management, subject to medical approval by a licensed provider. As low as $116 per month as of publication.
See microdosed tirzepatideMicrodosing tirzepatide for menopause: how telos rx frames it
telos rx prescribes microdosed tirzepatide for weight management only. It is not prescribed for menopause or its symptoms. Every plan is subject to medical approval by a licensed provider.
The process is asynchronous. You complete an online intake on your own time. A licensed provider reviews your history, labs if needed, and current medications, then messages you with a decision.
If you are prescribed, it is a weekly subcutaneous injection. Your provider sets the starting dose and any changes. Medication ships ready to inject, so there is no mixing or dose math on your side.
Microdosing GLP-1 and HRT
This is one of the most searched questions, so here is a direct answer. Hormone therapy decisions belong with your own clinician, such as your OB/GYN or a menopause specialist.
telos rx does not offer HRT, estradiol or progesterone. If you already use hormone therapy, list it in your intake. The telos rx provider reviews it alongside everything else before any decision.
The Hurtado study above is interesting, but it is one small retrospective cohort. It is not a reason to start, stop or change hormone therapy. That conversation is for you and your own clinician.
Safety points worth knowing in midlife
Side effects at any dose can include nausea, constipation and reduced appetite. Our guide to GLP-1 microdosing research covers what has been reported so far.
Some label points matter more around perimenopause and menopause:
- Contraception: the Zepbound label covers oral contraceptives. It advises switching or adding a barrier method for 4 weeks after starting and after each dose increase.
- Pregnancy: the label says it may cause fetal harm. Pregnancy is still possible during perimenopause.
- Thyroid history: the label lists a boxed warning about thyroid C-cell tumours.
- Muscle and bone: protein intake and strength training matter at midlife, with or without medication.
What a provider reviews in your intake
An asynchronous review is still a full medical review. It just happens in writing instead of on a call.
A licensed provider typically looks at:
- Your weight history and current health goals.
- Your menopause stage and any current hormone therapy.
- Other medications, including thyroid medication and contraception.
- History of pancreatitis, gallbladder disease or thyroid cancer.
- Screening questions for disordered eating.
- Recent labs, or a request for new ones if needed.
The provider may ask follow-up questions by message. If microdosed tirzepatide is not a good fit, they will say so. That is part of the process, not a failure.
Your dose is never chosen from a chart online. Charts circulating on social media are unreliable because concentrations differ between pharmacies. Your provider sets the dose for the product you actually receive.
Questions to ask before you start
Bring these to any provider, whether at telos rx or elsewhere:
- Is my goal weight management, or am I hoping to change menopause symptoms?
- Which product would I receive, branded or compounded?
- How will my dose be set and adjusted over time?
- How does this fit with my current HRT or other medications?
- Which side effects should prompt me to message you?
Want the broader picture? Read tirzepatide and menopause, semaglutide and menopause, and who qualifies for GLP-1.
The bottom line
Microdosing GLP-1 for menopause is a popular idea with very little direct research. The best data are small, standard-dose studies of weight in postmenopausal women.
If weight management is your goal, a licensed provider can review whether microdosed tirzepatide fits you. If symptoms are your goal, start with your own clinician.
Focused on weight, not hype
Start a private, asynchronous evaluation for microdosed tirzepatide, subject to medical approval by a licensed provider. Compounded tirzepatide is not FDA-approved.
Check if you qualifyFrequently Asked Questions
Does microdosing GLP-1 help with menopause symptoms?
There is no published microdose study on menopause symptoms such as hot flashes, sleep or mood. GLP-1 medications are not FDA-approved for menopause. The studies that exist look at weight in women after menopause, mostly at standard doses. If symptoms are your main concern, raise them with your own clinician, who can review options built for that purpose.
Is microdosing tirzepatide for menopause the same as taking Zepbound?
No. Zepbound is an FDA-approved branded tirzepatide pen with fixed doses set by its label. Compounded tirzepatide is a different product and is not FDA-approved. Microdosing means a provider prescribes a dose below the labelled schedule, which is off-label. Your provider explains which product you would receive and why.
Can I take a GLP-1 and HRT at the same time?
Some women do use both, and one retrospective study looked at that group. But the decision about hormone therapy belongs with your own clinician. telos rx does not prescribe HRT, estradiol or progesterone. If you already use hormone therapy, list it in your intake. Any plan is subject to medical approval by a licensed provider.
What is a microdose of tirzepatide?
Microdosing is not an FDA-recognised dosing category. It usually means a provider-prescribed dose below the standard labelled titration schedule. There is no agreed definition, and published evidence for sub-label doses is limited. Your provider sets the dose and adjusts it over time. Medication from telos rx ships ready to inject.
Who should not try microdosing GLP-1 during menopause?
The FDA labels list people who should not use tirzepatide, including those with a personal or family history of medullary thyroid carcinoma or MEN 2. People who are pregnant should not use it. A provider also screens for pancreatitis history, gallbladder issues and eating disorders. Eligibility is always decided by a licensed provider.
Is microdosing GLP-1 menopause weight gain support covered by insurance?
Compounded medication is usually paid out of pocket. telos rx lists microdosed tirzepatide as low as $116 per month on its product page as of publication. Plan details and the final price appear on that page. Branded drug coverage for menopause weight gain depends on your plan and your diagnosis.
telos rx is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.
Ready to see if it fits? Start your private evaluation with telos rx.